Citations

Clear

1055 citation(s) found for "Small, J C".

Primary squamous cell carcinoma of the small intestine: A population-based study.
Elhusseiny, Khaled , Alhayek, Bakr , Hajjar, Adnan Humam, Swaiti, Abdulazeez, Aljafari, Abdulmalek , Chen, Xuan, Saeed, Graham, Ali, Hassam, Alhayek, Bakr , Mahmoud, Alaa, Graham, Saeed S. , Ali, Hassam

Mayo Clinic

Journal of Clinical Oncology | January 12, 2026 | Volume: 44 | Issue: 2_suppl | Pages: 800-800

10.1200/jco.2026.44.2_suppl.800 Get It

800 Background: Primary squamous cell carcinoma (SCC) of the small intestine is exceedingly rare and associated with poor prognosis. Literature is currently limited to a few case reports, and, to our knowledge, this is the first population-based analysis of patients with small intestine SCC. This study aimed to identify patient demographics and predictors of survival outcomes. Methods: Patients with histologically confirmed primary SCC of the small intestine diagnosed between 2000 and 2022 were identified from the SEER database; autopsy-only cases were excluded. Patient demographics, tumor site, stage (SEER summary stage), and initial treatments were summarized. Overall survival (OS) was defined from diagnosis to death, with one-year OS estimated by Kaplan–Meier methods. Multivariate Cox proportional hazards models evaluated associations between patient variables (age, sex, race, residence, year of diagnosis, surgery, and chemotherapy) and mortality. All statistical analyses were performed using R version 4.4.2. Results: A total of 89 patients diagnosed with primary small intestine SCC were identified. The median age at diagnosis was 68 years; 43 % were female, and 67 % were non-Hispanic White. Most patients (82 %) resided in urban counties. Tumor site was mostly the duodenum (37 %), followed by ileum (16 %) and jejunum (10 %); 33 % were not otherwise specified. Among patients with a recorded stage, 45 % had localized disease, 38 % regional disease, and 17 % distant metastases. Initial treatment comprised surgery in 60 % of patients, chemotherapy in 25 %, and radiation in 10%. The median OS was approximately six months, and the one-year OS was 36.7 % (95 % CI 27.9–48.3). Women had a higher one-year OS (42 %) than men (33 %), although this difference was not statistically significant. In multivariable analysis, surgical resection was associated with a markedly lower hazard of death (HR = 0.43, 95 % CI 0.25–0.74). Chemotherapy was associated with an insignificantly improved survival (HR 0.54, 95 % CI 0.27–1.09). Additionally, rural residence (HR ≈ 2.9) and older age (HR ≈ 1.03) were independently associated with worse survival (p<0.05). Conclusions: This population-based study highlights the rarity and aggressiveness of primary small bowel SCC, with a median OS of six months. Surgical resection was strongly associated with improved survival (adjusted HR ≈ 0.43), reinforcing its role as the cornerstone of management. Chemotherapy showed a nonsignificant survival benefit, highlighting the need for prospective studies. The association of rural residence with higher mortality suggests disparities in access to care and underscores the need for strategies to improve early detection and referral. Overall, these findings support a multimodal approach centered on surgery and warrant further studies to elucidate pathogenesis and optimize systemic therapy.
Small cell carcinoma and large cell neuroendocrine carcinoma of colon and rectum: Incidence, survival outcomes, and comparison with well-differentiated neuroendocrine tumors (NETs) and adenocarcinoma.
Sun, Nora Yanyi, Shi, Qian, Jin, Zhaohui, Shi, Qian , McGarrah, Patrick W. , Hálfdánarson, Þorvarður R. , Jin, Zhaohui

Mayo Clinic

Journal of Clinical Oncology | January 12, 2026 | Volume: 44 | Issue: 2_suppl | Pages: 622-622

10.1200/jco.2026.44.2_suppl.622 Get It

622 Background: Colorectal small and large cell neuroendocrine carcinoma (SCNEC and LCNEC) comprise <1% of colorectal cancers and have poor prognosis. Detailed survival information is limited due to rarity. We analyzed survival outcomes using Survival, Epidemiology, and End Result (SEER) database (2000-2022) and compared with NETs and adenocarcinoma (AC). Methods: All patients with SCNEC, LCNEC, NETs or AC with colorectal primaries were extracted. AJCC stage was calculated with 8 th ed. TNM classification. Kaplan-Meier estimator, log-rank test, and Cox regression (including AJCC stage, surgery, radiation, and chemotherapy variables) were used to analyze survival outcomes. Results: Comparing colon and rectal primaries, the only significant mOS difference was in stage IV SCNEC (2 vs 7 months, p<0.0001). Comparing LCNEC and SCNEC, the only significant mOS difference was in stage IV colon SCNEC and LCNEC (2 vs 5 months, p<0.0001). Stage III and IV colorectal SCNEC and LCNEC had significantly shorter mOS than stage III and IV AC and NETs. In multivariate Cox regressions, surgery and chemotherapy were associated with significantly improved survival for both SCNEC and LCNEC at both primaries (p<0.001), while radiation was never significant. Conclusions: Most colorectal SCNEC and LCNEC patients present with stage IV disease. Stage IV colon SCNEC had significantly shorter mOS than both stage IV colon LCNEC and stage IV rectal SCNEC. Further research should explore early diagnosis and effective therapies for this rare, aggressive malignancy. Median overall survival (months) Colon SCNEC (n/mOS) Colon LCNEC (n/mOS) Colon NETs (n/mOS) Colon AC (n/mOS) SCNEC vs NETs in colon: P-value LCNEC vs NETs in colon: P-value SCNEC vs AC in colon: P-value LCNEC vs AC in colon: P-value SCNEC vs LCNEC in colon: P-value Rectal SCNEC (n/mOS) Rectal LCNEC (n/mOS) Rectal NETs (n/mOS) Rectal AC (n/mOS) SCNEC vs NETs in rectum: P-value LCNEC vs NETs in rectum: P-value SCNEC vs AC in rectum P-value LCNEC vs AC in rectum SCNEC vs LCNEC in rectum: P-value Colon SCNEC vs rectal SCNEC P-value Colon LCNEC vs rectal LCNEC: P-value Stage I 19/32 17/122 4496/NA 114,213/144 <0.0001 <0.0001 <0.0001 0.34 0.25 27/23 10/28 5185/NA 54,702/160 <0.0001 <0.0001 <0.0001 0.00047 0.88 0.99 0.24 Stage II 17/38 30/49 259/NA 121,757/106 0.0015 <0.0001 0.4 0.0068 0.65 17/16 3/NA 33/NA 38,417/106 <0.0001 0.57 <0.0001 0.87 0.3 0.065 0.55 Stage III 40/14 107/13 582/184 104,793/82 <0.0001 <0.0001 <0.0001 <0.0001 0.48 50/19 37/17 103/102 46,687/107 <0.0001 <0.0001 <0.0001 <0.0001 0.45 0.48 0.47 Stage IV 245/2 217/5 393/49 83,542/13 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 260/7 57/6 158/36 36,652/17 <0.0001 <0.0001 <0.0001 <0.0001 0.25 <0.0001 0.95
Desmoplastic Small Round Cell Tumor: Study of Cytomorphologic and Immunophenotypical Features in Seven Cases, One With Unusual Rhabdoid Morphology
Aryal, Sameer Chhetri , Shittu, Khalid , Mustafa, Mohamed , Alruwaii, Fatimah , Perry, Kyle, Yuan, Lisi , Yuan, Lisi , Chhetri Aryal, Sameer

Mayo Clinic

Diagnostic Cytopathology | January 11, 2026 | Volume: 54 | Issue: 4 | Pages: No page available

10.1002/dc.70079 | PMID 41520348 Get It

ABSTRACT Introduction Desmoplastic small round cell tumor (DSRCT) is a rare malignant mesenchymal neoplasm of polyphenotypic differentiation, characterized by EWSR1‐WT1 gene fusion. Despite multimodality therapy, the tumor carries poor prognosis. We report cytomorphological, immunohistochemical (IHC) and molecular features of seven cases of DSRCT from four patients. Materials and Methods A retrospective review of cytology smears, biopsies and molecular features of cases diagnosed as DSRCT at Department of Pathology, Henry Ford Health System, and Indiana University, USA between 2016 and 2022 were performed. A total of seven cases of DSRCT from four patients were included in this study. The cytological findings were correlated with concurrent or subsequent biopsy findings. Results All patients were male, with age ranging from 21 to 29 years. Two patients had primary tumor in the abdomen, one in the retroperitoneum, and one in the inguinal region. The tumors measured from 7.5 to 17 cm in size. Six out of seven cases showed typical hypercellular smears of small round cells with inconspicuous nucleoli, scant cytoplasm, and rare nuclear molding. The cytomorphology in Case no. 1 was unusual, showing discohesive pleomorphic tumor cells with large irregular nuclei, prominent nucleoli, occasional binucleation, and frequent mitotic activity. A subset of tumor cells demonstrated rhabdoid features. The tumor cells were positive for keratins (dot‐like), desmin, WT‐1, and CD15. In Case no. 4, the immunohistochemistry for desmin and WT‐1 was unusually negative reflecting the variability of the staining pattern. Three cases were positive for EWSR1 rearrangement by fluorescence in situ hybridization (FISH) and one positive for EWSR1‐WTI gene fusion by reverse transcriptase‐polymerase chain reaction (RT‐PCR). All seven cases had concurrent/subsequent surgical pathology diagnosis consistent with DSRCT. Conclusion Cytologic diagnosis for DSRCT is challenging but can be achieved with appropriate cytomorphology, IHC profiles, molecular studies, and demographic information. Rare rhabdoid differentiation can occur in DSRCT and can be present in effusion cytology.
Extraction of Treatments and Responses From Non–Small Cell Lung Cancer Clinical Notes Using Natural Language Processing
Sivarajkumar, Sonish , Edupuganti, Subhash , Lazris, David , Bhattacharya, Manisha, Davis, Michael K , Dressman, Devin, Thomas, Roby , Hu, Yan , Ren, Yang , Xu, Hua, Yang, P., Huang, Yufei , Wang, Yanshan, Wang, Yanshan , Davis, Michael , Xu, Hua , Yang, Ping , Wang, Yanshan

Mayo Clinic

JCO Clinical Cancer Informatics | January 8, 2026 | Volume: 10 | Issue: 1 | Pages: No page available

10.1200/cci-25-00138 | PMID 41505664 Get It

PURPOSE Manual extraction of treatment outcomes from unstructured oncology clinical notes is a significant challenge for real-world evidence (RWE) generation. This study aimed to develop and evaluate a robust natural language processing (NLP) system to automatically extract cancer treatments and their associated RECIST-based response categories (complete response, partial response, stable disease, and progressive disease) from non–small cell lung cancer (NSCLC) clinical notes. METHODS This retrospective NLP development and validation study used a corpus of 250 NSCLC oncology notes from University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center, annotated by physician experts. An end-to-end NLP pipeline was designed, integrating a rule-based module for entity extraction (treatments and responses) and a machine learning module using biomedical clinical bidirectional encoder representations from transformers for relation classification. The system's performance was evaluated on a held-out test set, with partial external validation for relation extraction on a Mayo Clinic data set. RESULTS The NLP system achieved high overall accuracy. On the UPMC test set (64 notes), the relation classification model attained an area under the receiver operating characteristic curve of 0.94 and an F1 score of 0.92 for linking treatments with documented responses. The rule-based entity extraction demonstrated a macro-averaged F1 score of 0.87 (precision 0.98, recall 0.81). Although precision was high for chemotherapy and most response types (1.00), recall for cancer surgery was 0.45. External validation at Mayo Clinic showed moderate relation extraction F1 scores (range: 0.51-0.64). CONCLUSION The proposed NLP system can reliably extract structured treatment and response information from unstructured NSCLC oncology notes with high accuracy. This automated approach can assist in abstracting critical cancer treatment outcomes from clinical narrative text, thereby streamlining real-world data analysis and supporting the generation of RWE in oncology.
NCCN Guidelines® Insights: Small Cell Lung Cancer, Version 2.2026
Ganti, Apar Kishor P., Loo, B., Bassetti, Michael, Chiang, Anne, D’Avella, Christopher , Daly, Megan, Dowlati, Afshin, Edelman, Martin, Florsheim, Charles, Grecula, J.C., Hann, Christine, Khalil, Maya, Lee, R., Merritt, Robert E. , Mohindra, Nisha , Molina, Julian R. , Moran, C Solis, Mulvey, Claire K. , Osmundson, Evan C., Patel, S. B., Patil, Tejas, Puri, S., Qin, Angel, Tailor, Tina D. , Waqar, Saiama N., Cassara, Carly J., Ramakrishnan, Swathi , Ganti, Apar Kishor , Loo, Billy W. , Badiyan, Shahed N. , Bassetti, Michael, Bestvina, Christine M. , Chiang, Anne, Choudhury, Noura J. , Daly, Megan, Gold, Kathryn Ann , Goldman, Jonathan W. , Hann, Christine L. , Lee, Robert P. , Malhotra, Jyoti Dhar , Pokharel, Saraswati , Qin, Angel , Sands, Jacob , Shields, Misty Dawn , Waqar, Saiama N

Mayo Clinic

Journal of the National Comprehensive Cancer Network | January 8, 2026 | Volume: 24 | Issue: 1 | Pages: No page available

10.6004/jnccn.2026.0002 | PMID 41671459 Get It

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Small Cell Lung Cancer provide recommendations for diagnostic workup, staging, and treatment. These NCCN Guidelines Insights highlight recent updates, with a particular focus on changes to systemic therapies and radiation treatment in the NCCN Guidelines for Small Cell Lung Cancer.
Probable Stricturing in Small Bowel Crohn Disease: In Support of SAR Consensus Recommendations
Dillman, Jonathan R., Rieder, Florian, Baker, Mark E. , Joel, Fletcher, Bruining, David H. , Kugathasan, Subra, Denson, Lee A. , Dillman, Jonathan R , Rieder, Florian , Kugathasan, Subra

Mayo Clinic

American Journal of Roentgenology | January 7, 2026 | Volume: 226 | Issue: 5 | Pages: No page available

10.2214/ajr.25.34245 | PMID 41499701 Get It

Disadvantaged neighbourhoods, modifiable risk factors, and cerebral small vessel disease in healthy midlife adults: the PREVENT Dementia study
Ntailianis, Georgios, Prats‐Sedano, Maria A , McKiernan, Elizabeth , McKeever, Anna , Su, Li , Dounavi, Maria‐Eleni , Bridgeman, Katie, Ritchie, Karen, Lawlor, Brian A, Paresh, Malhotra, Koychev, Ivan , Ritchie, Craig, O'Brien, John T, Investigators, the PREVENT Dementia, O’Brien, John T. , O'Brien, John Tiernan , Low, Audrey , Tsvetanov, Kamen A. , Carter, Stephen F. , Stefaniak, James D. , Nannoni, Stefania , Muñiz‐Terrera, Graciela , Bridgeman, Katie , Gregory, Sarah , Ritchie, Karen , LAWLOR, BRIAN A. , Naçi, Lorina

Mayo Clinic

Alzheimer's & Dementia | December 23, 2025 | Volume: 21 | Issue: S6 | Pages: No page available

10.1002/alz70860_106158 Get It

Abstract Background Individuals living in socioeconomically disadvantaged areas are disproportionately affected by dementia. However, the pathway leading from neighbourhood deprivation to cognitive symptoms is not well understood. To test our hypothesis that this relationship is associated with cerebral small vessel disease (SVD), we examined (1) whether neighbourhood deprivation related to midlife SVD burden and cognition, and (2) whether these links can be explained by modifiable lifestyle risk factors. Method In this multi‐centre cross‐sectional study, 514 cognitively healthy midlife participants aged 40‐59 years (median 52 years, 64.6% female) underwent clinical assessment and 3T MRI. Postcode data were used to obtain national indices of neighbourhood deprivation. To quantify SVD, we assessed white matter hyperintensities (WMH), perivascular spaces, cerebral microbleeds, and lacunes. Cognition was assessed using the Computerized Assessment of Information Processing (COGNITO) battery. Lifestyle risk factors were evaluated based on clinical data. Using multivariate statistics like structural equation modelling (SEM) and canonical correlation analysis (CCA), we examined associations between these constructs both globally and at the item‐level (i.e., distinction between domains of cognition/deprivation), to shed light on specific domains that could inform targeted prevention strategies. Result Neighbourhood deprivation related to greater prevalence of lifestyle risk factors ( r = 0.36, p < .001), greater SVD burden (b=0.18, p = .01; Figure 1), and greater cognitive impairment ( r = 0.36, p < .001), independent of educational attainment, sex, and age. These links with neighbourhood deprivation were largely driven by lifestyle factors relating to vascular health (sleep, physical activity, obesity, hypertension) (Figure 2), and cognitive deficits consistent with SVD (processing speed, visuospatial) (Figure 3). Residents of deprived neighbourhoods displayed greater prevalence of lifestyle risk factors, except alcohol consumption. Lower cognitive scores were most closely associated with deprivation domains of Crime and Living Environment (Figure 3). The DEPRIVATION→SVD path was mediated by lifestyle risk factors (z=2.57, p = .010), and the DEPRIVATION→COGNITION path was mediated by SVD (z=‐2.14, p = .032) (global SVD & hypertensive subtype, but not CAA‐SVD). Conclusion The pathway linking neighbourhood disadvantage to cognitive impairment at midlife is influenced by vascular risk factors and cerebrovascular burden. Tailored strategies could promote resilience against dementia by promoting health behaviours aligned with the community's unique needs.
Healthcare Resource Utilization and Costs in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia Treated With Covalent Bruton's Tyrosine Kinase Inhibitors: Real‐World Impact of Cardiovascular Adverse Events
Nigris, Enrico De, Leng, Siyang , Farooqui, Mohammed Z.H. , Yapici, Halit O. , Weimer, Ian , Jiao, Weiqi, Hyatt, Hayden W. , Lodaya, Kunal , Dingli, David , Hyatt, Hayden W , Dingli, David , Obeng‐Kusi, Mavis , Zhang, Xuan

Mayo Clinic

Cancer Medicine | December 22, 2025 | Volume: 14 | Issue: 24 | Pages: No page available

10.1002/cam4.71484 | PMID 41423437 Get It

ABSTRACT Introduction Although covalent Bruton's tyrosine kinase inhibitors (cBTKis) have transformed treatment of chronic lymphocytic leukemia and small lymphocytic leukemia (CLL/SLL), cBTKi‐related cardiotoxicity is a known side effect. This real‐world study evaluated incident cardiovascular adverse events (CVAE), healthcare resource utilization (HCRU), and costs among patients with CLL/SLL receiving cBTKis. Methods Adult patients with CLL/SLL who initiated ibrutinib or acalabrutinib treatment (index date) between 2020 and 2023 were identified using US claims data and followed up to 36 months post‐index. Incident CVAEs (not present pre‐index) were assessed during cBTKi treatment and patients were stratified by CVAE status. HCRU and costs were evaluated per 1000 patient‐months (PPPM). Results Overall, 2069 patients were identified (mean age of 73.7 ± 9.1 years, 40.4% female) with a mean treatment‐specific observation period of 11.4 ± 9.5 months. At least one incident CVAE was observed in 442 (21.4%) patients. The incidence rate was 21.6 PPPM for hypertension, 8.9 PPPM for atrial fibrillation, 8.6 PPPM for ventricular arrhythmias, and 8.3 PPPM for atrial flutter. Patients with incident CVAEs had significantly more total medical service days PPPM (4334 vs. 3138, p < 0.001), primarily driven by increased inpatient (690 vs. 230), outpatient (2798 vs. 2425), other visit (662 vs. 375), and ER days (184 vs. 109) than those without CVAEs. Total healthcare costs (PPPM) were substantially higher for patients with incident CVAEs ($20,250,560 vs. $17,413,460, p < 0.001) mainly due to higher inpatient ($3,417,948 vs. $915,839, p < 0.001), outpatient ($2,415,060 vs. $1,769,628, p < 0.01), and ER costs ($186,820 vs. $87,585, p < 0.001). Conclusions The observed class‐effect of high CVAEs with cBTKis underscores the unmet need for safer, more selective agents for CLL/SLL treatment. The HCRU and economic burden remain high for CLL/SLL, especially among patients experiencing CVAEs during cBTKi treatment. These findings emphasize the importance of optimizing clinical management to reduce CVAE risk and downstream impacts on HCRU and costs.
Recommendations for the diagnostic work‐up of cutaneous small vessel vasculitis – Position Statement of the European Academy of Dermatology and Venereology Vasculitis and Vasculopathy Task Force
Alpsoy, Erkan , Caproni, Marzia , Wetter, David A. , Goebeler, Matthias , Schneider, Stefan W. , Sălăvăstru, Carmen , Llamas‐Velasco, Mar , Akyol, Melih , Dutz, Jan , Jachiet, M. , Kawakami, Tamihiro , Piette, Warren W., Ratzinger, Gudrun , Szepietowski, Jacek C. , Schneider, Stefan W , Llamas-Velasco, Mar , Marzano, Angelo Valerio , Jachiet, Marie , Mariotti, Elena Biancamaria , Maronese, Carlo A , Monfort, Jean-Benoît , Ratzinger, Gudrun , Werth, Victoria P , Szepietowski, Jacek C , Caproni, Marzia , Levell, Nick J. , Maronese, Carlo Alberto , Micheletti, Robert , Werth, Victoria P. , Sunderkötter, Cord

Mayo Clinic

Journal of the European Academy of Dermatology and Venereology | December 16, 2025 | Volume: 40 | Issue: 6 | Pages: 946-962

10.1111/jdv.70249 | PMID 41399325 Get It

Abstract Background Small vessel vasculitides (SVV) comprise a heterogeneous group of cutaneous SVV (CSVV) that can be skin‐limited or systemic. Given their diverse forms and symptoms and the lack of a standardized diagnostic approach, it is crucial to establish clear and consensus‐driven recommendations for diagnosis. Objectives To standardize diagnosis for the detection of the type, extent, potential causes or underlying conditions of CSVV. Methods International experts comprised the panel. The Delphi panel data was collected through two rounds of questionnaires. Agreement was measured using an 11‐point Likert scale (0 = strongly disagree, 10 = strongly agree). A 7‐vote minimum was required for agreement on each statement. Delphi panel statements scoring 3–7 were discussed during the meeting. Results 20 experts participated in the first round of the Delphi panel, while 17 experts took part in the second. They agreed that the diagnosis of CSVV relies on a combination of clinical manifestations, laboratory findings and histopathology. Palpable purpura on the lower extremities is recognized as the most reliable hallmark for most SVV and a sign of immune complex vasculitis. When the latter is suspected, a skin biopsy for direct immunofluorescence (DIF) should be obtained from an early, partially blanchable macule because the type of perivascular immunoglobulin is important for further diagnosis. The proper selection of biopsy sites for routine HE biopsy depends on the morphology of lesions. A comprehensive medical history and selected laboratory testing should be conducted to investigate organ involvement, potential causes and associated conditions. The extent of diagnostic procedures should be based on the severity, duration, systemic symptoms and recurrence of SVV. Conclusions Experts reached a strong consensus on the management of CSVV patients, culminating in the first International Consensus Statement for adult CSVV. This statement proposes a practical management algorithm and underscores the importance of collaboration in rare diseases management.